Physician profile
Chad E Weldon
NPI 1942520960
$6,893.28
in general payments reported to CMS, 2019-2025
50 companies · $912 in 2025
The $912 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $950 · 2021: $1,334 · 2022: $1,108 · 2023: $691 · 2024: $774 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,246.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $915.58 | 2021-2025 | Qulipta, Vraylar, Viberzi |
| Amgen INC. | $532.17 | 2019-2025 | Evenity |
| Lilly USA, LLC | $463.26 | 2019-2024 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $435.79 | 2019-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $398.88 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $280.19 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $268.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Mylan Specialty L.P. | $220.35 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.62 | 2019-2024 | Xifaxan |
| Pfizer INC. | $203.43 | 2019-2025 | |
| Amarin Pharma, INC. | $202.30 | 2019-2022 | |
| Astellas Pharma US INC | $185.82 | 2019-2021 | |
| Adlon Therapeutics L.P. | $118.86 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.18 | 2019-2025 | Jardiance |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.